Provide testing, processing, and storage services for umbilical cord blood. Facilitate donor matching for cord blood samples. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $994.7M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 40% — still a thick cushion, though costs have been eating into it lately.
There is $994.7M in the vault; even if every debt were paid off, $994.7M would remain.
Over the last 12 months, company executives reported 42 buys and 1 sell. Management buying with its own money is usually read as a good sign.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.